Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
American Heart Journal.
Times cited: 63
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
Times cited: 5
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
Times cited: 307